Showing results (381-390 of 460) with videos related to

Sort By:
Pageof 46
The Journal of Infectious Diseases|July 4, 1998
Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccineR L Ashley, F M Crisostomo, M Doss, et al.
The New England Journal of Medicine|June 14, 1984
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infectionJ M Douglas, C Critchlow, J Benedetti, et al.
Sexually Transmitted Diseases|July 1, 1993
Underestimation of HSV-2 seroprevalence in a high-risk population by microneutralization assayR L Ashley, J Dalessio, J Dragavon, et al.
The Journal of Infectious Diseases|February 1, 1997
Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupW B Paxton, R W Coombs, M J McElrath, et al.
Blood|February 26, 2000
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonalityH Soudeyns, G Campi, G P Rizzardi, et al.
The Journal of Infectious Diseases|December 1, 1993
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group NetworkR B Belshe, M L Clements, R Dolin, et al.
Obstetrical & Gynecological Survey|July 1, 1988
Colposcopic manifestations of cervical and vaginal infectionsJ Paavonen, C E Stevens, P Wølner-Hanssen, et al.
Sexually Transmitted Diseases|April 1, 1990
The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpesL A Koutsky, R L Ashley, K K Holmes, et al.
The Journal of Infectious Diseases|February 10, 1999
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defectsW C Goh, J Markee, R E Akridge, et al.
Lancet (London, England)|March 9, 1991
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoproteinE L Cooney, A C Collier, P D Greenberg, et al.
Pageof 46